RxDoctor Payments Data

Haresh Jani, MD

Cardiovascular Disease · Jackson, MINPI 1760486583

Payments from drug & device makers

$945in general payments, 2019–2025

Across 57 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$194
  • Pfizer$135
  • Johnson & Johnson$110
  • Astellas Pharma US Inc$96
  • E.r. Squibb & Sons, L.L.C.$75
  • Novo Nordisk$74
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$91897%
  • Education$273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$945 in reported general payments places this provider in the 30th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$233,704
Medicare patients
807
Services billed
2,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban239$298,165
XareltoRivaroxaban144$170,867
EntrestoSacubitril/Valsartan106$162,501
JardianceEmpagliflozin77$115,854
FarxigaDapagliflozin Propanediol82$102,383
Repatha SureclickEvolocumab70$70,642
Repatha SyringeEvolocumab51$58,103
JanuviaSitagliptin Phosphate37$39,910
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$26,968
MultaqDronedarone Hcl13$22,801
TrulicityDulaglutide15$19,452
OzempicSemaglutide13$12,279
Incruse ElliptaUmeclidinium Bromide18$11,255
Icosapent Ethyl17$10,100
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$298,165239 claims
Johnson & JohnsonXarelto$110$170,867144 claims
NovartisEntresto$194$162,501106 claims
Boehringer IngelheimJardiance$47$115,85477 claims
AstraZenecaFarxiga$44$102,38382 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta$15$46,26952 claims
Sanofi-aventis U.S. LLCMultaq$37$22,80113 claims
Lilly USA, LLCTrulicity$11$19,45215 claims
Novo NordiskOzempic$74$12,27913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →